Amro Albanna (00:03): All right folks, those that are just joining us, we're going to go ahead and wait for a few seconds just to make sure that the recording is capturing everything. I do see more guests joining right n

Amro Albanna (00:03):

All right folks, those that are just joining us, we're going to go

ahead and wait for a few seconds just to make sure that the recording is capturing everything. I do see more guests joining right now,

and Jeff, Don, we are almost there. All right, very good. Welcome everybody. Thank you for joining our Aditxt weekly update. And with

that I'm going to go ahead and ask Jeff... I know Jeff, I ask you this all the time, and I know it sounds like you've done it over and

Jeff Ramson (00:38):

Amro Albanna (00:39):

You never know who's joining us, so please go ahead and introduce yourself.

Jeff Ramson (00:43):

Sure, sure. So I'm Jeff Ramson, I run PCG advisory and I've been a

long-time investor and advisor to Aditxt and I'm working with Amro on corporate communications, and very happy to be joining these weekly

Amro Albanna (01:00):

Wonderful, thank you Jeff. Don, really appreciate you joining us today.

You are the president and CEO of Appili. We have some discussion today to go over Appili. Why don't you go ahead and get us started with

Okay, thank you very much. As Amro said, I'm the president and CEO

of Appili, and we are really excited to be here talking today. So I wanted to thank Amro and Jeff for inviting us and giving us this opportunity.

What I wanted to do is just jump into some topics that are big for Appili. As you know, Appili is a tiny biotech company that focuses

on infectious diseases and medical countermeasures. And so I thought it might be helpful just to go back and put some context around the

types of things that we're doing. So one of the things, I know people hear about this and they ask frequently, is that drug-resistant

infections seem to be increasing, both globally and in the U.S. And I just want to give you a few facts to set things in your mind properly.

So when you look at some of the recent news, there have been outbreaks around the world, cholera outbreak in Angola, measles in the U.S.,

Marburg in Tanzania, MERS in Saudi Arabia, Sudan virus in Uganda, and a new Congo virus that they haven't quite identified yet has outbroken.

And you would think, "Wow, that's a lot of stuff that's going

on. That's really big." Well, that was just March. All those things occurred in March. If you look since the year 2000, and we all

will recall the effect that the pandemic had on us, the COVID-19 pandemic, but I don't know if you're aware of this, since the year 2000

there have been 10 at or near pandemic outbreaks. So these are outbreaks that have occurred that had the ability to become a pandemic,

but fortunately those were all controlled and things like SARS and MERS and Plague and Ebola and Zika and smallpox probably heard of Mpox

and flu. So all those things are occurring in the background. They all have the potential to outbreak and become something like COVID-19.

And that's why the infectious disease area is so important and one of the things that we need to pay attention to going forward, as both

an industry, as well as the public health component of our governments, and just we as individuals as well.

I thought it might be helpful to talk about some of the factors that

help increase the spread of those disease. And one of those, I was just looking up the other day, I had no idea that the population of

the world was eight and a half billion people. I looked at what it was when I was born, and I was born a while ago, granted, it was only

3.1 billion people. And so over the course of my lifetime, the population of the world has grown more than twofold. But you know what

didn't grow more than twofold? The landmass, where people have to live. So we're now pushing twofold more people into the same amount

of area that we had before. And then also, I'm not sure if everyone's aware of this, but there's been a big migration from rural home

settings to urban home settings. In 1950, the percent of people that lived in a rural, I'm sorry, in an urban setting globally was only

And today it's 55% and it's anticipated to be 20... In 2050 it's expected

to be 68%. And so what you're seeing is a large exodus from rural areas into urban areas, and what does that mean? So if you think about

it, you are now packing more and more people into smaller and smaller spaces. And so what it means is it makes it much easier for infectious

diseases, in particular those that are transmitted by human contact, respiratory viruses, things like that. It makes it much, much easier

for them to actually be transmitted amongst a larger population. The next trend that I think was very important to understand too is globalization.

So if you look, travel and trade have dramatically increased throughout the years. I was surprised to find this, but there are 2 million

people that take international flights every day. And so what that does is that allows people to travel from areas where potentially some

of these viruses are much more common, into areas that don't have them yet.

And it makes it very easy for viruses to hitch a ride, or bacteria

to hitch a ride, and get to new locations. Trade too, shipping lots of goods allows something like this to happen. The U.S. imports 50%

of our fruit from international sources, 80% of the seafood comes from international sources. So we have just given all these bugs, these

infectious diseases, plane tickets to come to different geographies just by all the shipping and global trade that we have. And the other

thing just to mention is wars. Wars also contribute to the spread of disease as well, because you've got soldiers coming into and out

of regions where they hadn't been before. There are a couple of other factors I want to discuss and they can be considered politically

Amro Albanna (05:52):

So Don, forgive me just before we get into, it's really important for

us as we begin, or as we put these Aditxt weekly updates together, I know there are more and more people joining. Some people obviously

haven't had the background and it's important for us to always put it in context. So Aditxt is a business platform that is designed to

identify opportunities and identify companies that address some of our biggest or most pressing health challenges. If we're successful

at the acquisition we'll bring them in-house, we support the growth of the company with the goal of ultimately positioning the company

for growth. So just to make sure again, that since this is live and it's recorded, just for future, Appili is a company that we are currently

in the process of acquiring, and Appili is focused on infectious diseases. So that background, Don, that you shared is really, really

important because just to make sure again people understand where Appili fits.

We talked about ad immune, we talked about Pearsanta in the past, couple

other subsidiaries. And Appili is a company that we are in the process of acquiring. And we'll talk about the status, we'll talk about

obviously some of the challenges that we need to address, just like and what we did with Evofem. So Don, you gave us a pretty good idea

about infectious diseases. It's a real problem. Everybody can see that, but I think most of the public, most people do not realize that

actually infectious diseases are becoming more spread, more lethal, if that is... Why don't you just kind of give us the key factors of

why that is after obviously all the advancements in medicine, why is that the case today?

Yeah, talking about the spreading, and that's one of the next factors

I wanted to talk about. Climate change is one of those, and by climate change what we mean are warming air temperatures. If you look at

the United States, the temperatures over the last 50 years have been steadily increasing. Now what does that mean for infectious disease?

What it means is that as the land, as the U.S. starts to warm more and more, it allows the geographic expansion of both vectors and carriers

of disease. And just so everyone understands, the carrier of a disease might be a rodent, like a rabbit or a rat or something like that.

And vectors are arthropods that would bite the carriers and then later bite humans transferring the disease back and forth. Those are

things like mosquitoes, flies, sand flies, things like that. So that is probably one of the big factors that really is helping us see

this spread of disease into areas where we are now.

The other thing you asked about, what's causing them to be more pathogenic

over time, and I think largely what you're seeing is the mutations of viruses and bacteria. Generally speaking mutations are thought to

just make them a little bit less pathogenic, but because there are so many mutations, some of them can actually... Have increased survival

abilities and also become more pathogenic. And what they're doing is they're trying to find good ways to abate your immune system so that

if they can do that better, then they can become more pathogenic as well. So there's a couple of good reasons for that.

Amro Albanna (09:21):

Where does Appili fit right now, Don? Commercial, as an opportunity

to address these challenges, how does Appili come at it? Why Appili and really where the opportunity is?

Sure, yeah, let's talk about that. So Appili, we think of ourselves

as a scrappy little biotech company who've been created to deliver innovative drug development programs, unmet patient needs across a

broad spectrum of infectious diseases and on medical countermeasures. So our vision is to be one of those leaders in combating infectious

diseases for underserved populations and be very involved in preventing or treating infectious diseases, neglected tropical diseases,

and developing medical countermeasures to help people worldwide. So as a company, we have a very small, but a very experienced team. The

core group at Appili has more than 140 years of pharma biotech experience. We have collectively filed a hundred INDs, 60 ANDAs, 22 NDA

and BLA filings. And we've worked across a variety of different types of products from rare diseases, animal rule, pediatric indications,

and all types of work. So with Appili you get this focus on infectious disease, a lot of experience in developing products, and then we

also have significant fundraising experience as well, and that helps to fund our research and development.

So historically we've raised more than $47 million in non-dilutive

funds. And I think as you saw from the press release, we've recently submitted proposals for additional four projects that would amount

to $117 million if awarded. So our team has had a lot of experience putting together those types of proposals and have done this very

successfully in the past. Not all at Appili, because Appili is still a young company doing this, but people came from a number of other

companies where they did do this type of work.

Amro Albanna (11:16):

Got it. Sorry Don, go ahead.

No, I was going to say, and then our portfolio. So our portfolio right

now is it's basically diversified across a number of different types of infectious diseases. So we do have a product that's currently